References
- Hughes A. CDK inhibitors in 3D: problems with the drugs, their development plans or their linkage to disease?. Gene Ther Mol Biol 2006;10:41–54.
- Morein B, Blomqvist G, Hu K. Immune responsiveness in the neonatal period. J Comp Pathol 2007;137(Suppl. 1):S27–S31.
- Wang Z.-P. Saponins as anticancer agent 2005. United States Patent 20050175623 A1.
- Morein B, Hu K, Lovgren K, et al. New ISCOMs meet unsettled vaccine demands. In: Singh M, editor. Vaccine adjuvants and delivery systems. Hoboken, NJ: John Wiley & Sons, Inc.; 2007. pp 191–222.
- Hu K, Berenjian S, Larsson R, et al. Nanoparticulate Quillaja saponin induces apoptosis in human leukemia cell lines with a high therapeutic index. Int J Nanomed 2010;5:51–62.
- Larsson R, Kristensen J, Sandberg C, et al. Laboratory determination of chemotherapeutic drug resistance in tumor cells from patients with leukemia, using a fluorometric microculture cytotoxicity assay (FMCA). Int J Cancer 1992;50:177–185.
- Brown G, Hughes P. Retinoid differentiation therapy for common types of acute myeloid leukemia. Leuk Res Treat 2012;2012:939021.
- Corre I, Pineau D, Hermouet S. Interleukin-8: an autocrine/paracrine growth factor for human hematopoietic progenitors acting in synergy with colony stimulating factor-1 to promote monocyte-macrophage growth and differentiation. Exp Hematol 1999;27:28–36.
- Friedland JS, Constantin D, Shaw TC, et al. Regulation of interleukin-8 gene expression after phagocytosis of zymosan by human monocytic cells. J Leukoc Biol 2001;70:447–454.
- Bach S, Knockaert M, Reinhardt J, et al. Roscovitine targets, protein kinases and pyridoxal kinase. J Biol Chem 2005;280: 31208–31219.
- Lapenna S, Giordano A. Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov 2009;8:547–566.
- Ciechanover A. Proteolysis: from the lysosome to ubiquitin and the proteasome. Nat Rev Mol Cell Biol 2005;6:79–87.
- Rastogi N, Mishra DP. Therapeutic targeting of cancer cell cycle using proteasome inhibitors. Cell Div 2012;7:26.
- Frezza M, Schmitt S, Dou QP. Targeting the ubiquitin-proteasome pathway: an emerging concept in cancer therapy. Curr Top Med Chem 2011;11:2888–2905.
- Nowak D, Stewart D, Koeffler HP. Differentiation therapy of leukemia: 3 decades of development. Blood 2009;113:3655–3665.
- Zhou Y, Kato H, Asanoma K, et al. Identification of FOXC1 as a TGF-beta1 responsive gene and its involvement in negative regulation of cell growth. Genomics 2002;80:465–472.
- Murata M, Eto Y, Shibai H, et al. Erythroid differentiation factor is encoded by the same mRNA as that of the inhibin beta A chain. Proc Natl Acad Sci USA 1988;85:2434–2438.
- Legras S, Gunthert U, Stauder R, et al. A strong expression of CD44-6v correlates with shorter survival of patients with acute myeloid leukemia. Blood 1998;91:3401–3413.
- Liu J, Bi G, Wen P, et al. Down-regulation of CD44 contributes to the differentiation of HL-60 cells induced by ATRA or HMBA. Cell Mol Immunol 2007;4:59–63.
- Ikewaki N, Tamauchi H, Inoko H. Decrease in CD93 (C1qRp) expression in a human monocyte-like cell line (U937) treated with various apoptosis-inducing chemical substances. Microbiol Immunol 2007;51:1189–1200.
- Browning DD, Diehl WC, Hsu MH, et al. Autocrine regulation of interleukin-8 production in human monocytes. Am J Physiol Lung Cell Mol Physiol 2000;279:L1129–L1136.
- Emadi S, Clay D, Desterke C, et al. IL-8 and its CXCR1 and CXCR2 receptors participate in the control of megakaryocytic proliferation, differentiation, and ploidy in myeloid metaplasia with myelofibrosis. Blood 2005;105:464–473.
- Heeney JL, Teeuwsen VJ, van Gils M, et al. Beta-chemokines and neutralizing antibody titers correlate with sterilizing immunity generated in HIV-1 vaccinated macaques. Proc Natl Acad Sci USA 1998;95:10803–10808.
- Malumbres M, Pevarello P, Barbacid M, et al. CDK inhibitors in cancer therapy: what is next?. Trends Pharmacol Sci 2008;29:16–21.